Clinical Trial Results:
Efficacy and Tolerability of Menthacarin in Patients (>= 18 years old) suffering from symptoms of Irritable Bowel Syndrome (IBS)
Summary
|
|
EudraCT number |
2014-004702-14 |
Trial protocol |
DE |
Global end of trial date |
15 Jun 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 Jun 2020
|
First version publication date |
14 Jun 2020
|
Other versions |
|
Summary report(s) |
530079.01.302 Summary of results 2020_05_29 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
530079.01.302
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN31630783 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Dr. Willmar-Schwabe GmbH & Co. KG
|
||
Sponsor organisation address |
Willmar-Schwabe-Str. 4, Karlsruhe, Germany, 76227
|
||
Public contact |
Head of Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, 49 7214005573,
|
||
Scientific contact |
Head of Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, 49 7214005573,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
16 Nov 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Jun 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Jun 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the efficacy and tolerability of Menthacarin® in patients (>= 18 years old) suffering from symptoms of IBS.
|
||
Protection of trial subjects |
Possibility to withdraw informed consent. Monitoring of adverse events and laboratory parameters.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
11 Jul 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 226
|
||
Worldwide total number of subjects |
226
|
||
EEA total number of subjects |
226
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
205
|
||
From 65 to 84 years |
21
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
Twenty-two trial centres in Germany participated in the trial. | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
A total of 226 patients were screened for enrollment into the trial. Four patients were re-screened and received a new patient number. Therefore, 230 patient numbers exist. Twenty-six of the 226 screened patients were not randomized and did not receive trial medication. One patient was randomized but did not take study medication. | |||||||||||||||||||||||||||
Pre-assignment period milestones
|
||||||||||||||||||||||||||||
Number of subjects started |
226 | |||||||||||||||||||||||||||
Number of subjects completed |
199 | |||||||||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
||||||||||||||||||||||||||||
Reason: Number of subjects |
Screening Failures: 20 | |||||||||||||||||||||||||||
Reason: Number of subjects |
Consent withdrawn by subject: 5 | |||||||||||||||||||||||||||
Reason: Number of subjects |
Scheduling Issues: 2 | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Treatment period 1 (overall period)
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Assessor | |||||||||||||||||||||||||||
Blinding implementation details |
Double blind
|
|||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Menthacarin | |||||||||||||||||||||||||||
Arm description |
Menthacarin (Mentha x piperita L. (90 mg WS® 1340) and Carum carvi (50 mg WS® 1520)), 1 soft capsule taken 2 times daily (1-1-0) | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
WS® 1340 / WS® 1520
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, soft
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
1-1-0
|
|||||||||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||||||||
Arm description |
Placebo, 1 soft capsule taken 2 times daily (1-1-0) | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, soft
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
1-1-0
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: In total, 27 of the 226 subjects screened for inclusion into the study were not included into the baseline period. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Menthacarin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Menthacarin (Mentha x piperita L. (90 mg WS® 1340) and Carum carvi (50 mg WS® 1520)), 1 soft capsule taken 2 times daily (1-1-0) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo, 1 soft capsule taken 2 times daily (1-1-0) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The FAS included all patients of the Safety analysis set who had at least one measure of the primary efficacy parameter (pain score for 7 days to allow the calculation of a weekly average) during the active treatment period after baseline visit and patients who terminated the trial prematurely because of lack of efficacy or unexpected improvement/remission of disease (after at least 14 days of treatment) or an AE for which a causal relationship to trial medication was not excluded (even if the patient had no efficacy measurement during active treatment period).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Menthacarin
|
||
Reporting group description |
Menthacarin (Mentha x piperita L. (90 mg WS® 1340) and Carum carvi (50 mg WS® 1520)), 1 soft capsule taken 2 times daily (1-1-0) | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo, 1 soft capsule taken 2 times daily (1-1-0) | ||
Subject analysis set title |
Full Analysis Set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
The FAS included all patients of the Safety analysis set who had at least one measure of the primary efficacy parameter (pain score for 7 days to allow the calculation of a weekly average) during the active treatment period after baseline visit and patients who terminated the trial prematurely because of lack of efficacy or unexpected improvement/remission of disease (after at least 14 days of treatment) or an AE for which a causal relationship to trial medication was not excluded (even if the patient had no efficacy measurement during active treatment period).
|
|
|||||||||||||
End point title |
Change in abdominal pain (using an 11 point numeric rating scale (NRS)) [1] | ||||||||||||
End point description |
Note: This document in its section "End points" specifies commercially confidential information of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe referred to in Article 81 Section (4) b) Regulation (EU) 536/2014 that is a trade secret and released by the holder for purposes of Regulation (EU) 536/2014 only under the conditon of confidence. Trade secrets may not - even in part - be published or released to third parties other than to competent authorities without express permission of the trade secret holder.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 0 and Day 28
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The reported results are chosen freely. See document for a complete description of the statistical methods and results. Statistical analyses were conducted for the end point. Refer to the attached summary of results for details. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
12 weeks
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Efficacy and tolerability of Carmenhtin in patients suffering from irritable bowel syndrome
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
No active treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
No active treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Menthacarin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Study medication | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |